Production of Mucormycosis drug increased five-fold in India: Govt

at 4:00 pm
Maritime India Summit
MoS Chemicals and Fertilizers Mansukh Mandaviya (File Pic)

New Delhi: Production of Amphotericin-B drug, prescribed for treatment of Mucormycosis or Black Fungus, has been scaled up by nearly five times in India and it is expected to cross 3.75 lakh vials this month, Union Minister of State for Chemicals and Fertilisers Mansukh Mandaviya said today.

“India has increased domestic production remarkably by more than fivefold. Domestic production of Liposomal Amphotericin-B was just 62,000 vials in April, 2021 and now it is expected to cross 3.75 lakh vials in June, 2021,” he tweeted.

“While increasing domestic production, India also placed order to import 9,05,000 Liposomal Amphotericin-B vials through M/s Mylan,” he said.

“On 16th June,2021, active cases of Mucormycosis were 27,142. Even in the future, if cases of Black fungus increases. India is prepared to have more than sufficient availability of Amphotericin B drug and other drugs which are required to treat patients of Mucormycosis,” the Minister said.

India is leaving no stone unturned to boost the availability of  Amphotericin B drugs in the country,” he added.

Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers has allocated a total 7,28,045 vials ofLiposomal Amphotericin B to all the states and Central institutions till June 17.